CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 125 enrolled
Drug / intervention
Influenza Virus Quadrivalent Inactivated Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03673345
NCT03673345Phase 4Completed

Effect of Influenza Vaccination or Infection on the Development of Protective Immunity in Children

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Sep 17, 2018·Updated Mar 18, 2022

In Brief

A Phase 4 clinical trial evaluating Influenza Virus Quadrivalent Inactivated Vaccine for Influenza and Influenza Immunisation. Completed, enrolled 125 participants across 1 site.

Detailed Summary

This study is a prospective surveillance of the immune response to seasonal vaccination in healthy children. The study will enroll a total of approximately 220 subjects. 140 children will be vaccinated with inactivated influenza vaccine (IIV) and will be divided into 4 age cohorts: 20 children between 6-12 months of age, 60 children greater than 12 months of age and born after 2009, 30 children with a birth date between 2006 and 2009, and 30 children with a birth date between 2003 and 2006. 80 children presenting with natural influenza infection prior to receipt of influenza vaccination also will be divided into 4 age cohorts: 20 children between 3-12 months of age, 20 children greater than 12 months of age with a birth date after 2009, 20 children with a birth date between 2006 and 2009, and 20 children with a birth date between 2003 and 2006. Influenza vaccines will be administered using age-appropriate guidelines in all years of the study: Fluzone 0.25 mL administered intramuscularly to children between 6 and 35 months of age and 0.5 mL to children 36 months of age and older. Subjects will be seen at one domestic site and their participation duration is 2 influenza seasons plus 1 optional season. The primary hypothesis being tested in this study is that there will be differences in the specificity, magnitude and functionality of CD4 T cell and B cell reactivity in a cohort of children depending on early childhood exposures. The primary objective of this study is to evaluate the relationship between influenza virus exposure, infection and vaccine history, and CD4 T cell reactivity in a cohort of children with well documented influenza exposures.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedSep 17, 2018
Enrollment StartSep 25, 2018
Primary CompletionDec 22, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 7.8 years ago

Interventions

Influenza Virus Quadrivalent Inactivated Vaccinebiological

A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).